Endpoints News

Macrocycle shop gets $45M Series B		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

Mon T W Th F

16 March, 2026

AI-driven drug discovery is already reshaping pipelines. But algorithms alone won’t get a drug to the clinic. Join us for a free virtual program — then continue the conversation at an in-person only fireside chat and happy hour in Boston. Reserve your spot.

presented by

5 ways to secure biotech funding in 2026

SPOTLIGHT

Who’s leading LGBTQ+ inclusion in biopharma? Nominate them for Endpoints’ annual report

news

Structure Therapeutics reports more Phase 2 data for oral GLP-1

Unnatural Products gets $45M to test decadelong work on macrocyclic peptides

Mar 24

11:30 am ET

From structure to selectivity: Federated AI for collaborative binding affinity prediction

in case you missed it

Roivant CEO, bullish on growth, isn't waiting for a 'mercurial master' to buy up assets

Danish biotech Gubra plots Roivant-like model to churn out new companies

A LAG-3 pioneer fails in Phase 3, pouring more cold water on a once-hot cancer target

Peer Review

Flagship startup loses CEO to Ipsen; Ionis to shed nearly six decades of board experience

Ultragenyx’s gene therapy hits key endpoint in Phase 3 trial for blood ammonia disease

News Briefing

Y-mAbs terminates radiopharma trial; GSK gets expanded use for Arexvy

Grail names new CEO as Bob Ragusa retires

Middle East war disrupts pharma air routes, risks cancer drugs supply

The deadline for nominations for this year’s LGBTQ+ Leaders in Biopharma special report is fast approaching (March 25), so make sure you send them soon.

Reynald Castaneda

Deputy Editor, Endpoints News

2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com

Endpoints Studio